AlzChem Group AG

  • WKN: A2YNT3
  • ISIN: DE000A2YNT30
  • Land: Deutschland

Nachricht vom 03.06.2019 | 09:00

AlzChem Group AG: Andreas Niedermaier becomes new CEO - Dr. Georg Weichselbaumer appointed to the Management Board effective July 1, 2019

DGAP-News: AlzChem Group AG / Key word(s): Personnel

03.06.2019 / 09:00
The issuer is solely responsible for the content of this announcement.


AlzChem Group AG: Andreas Niedermaier becomes new CEO - Dr. Georg Weichselbaumer appointed to the Management Board effective July 1, 2019


Trostberg, June 3, 2019 - The Supervisory Board of AlzChem Group AG has decided to appoint Mr. Andreas Niedermaier (CFO) as the new CEO with effect from July 1, 2019, in view of the resignation of the current CEO Mr. Ulli Seibel as of December 31, 2019. In this function, Mr. Niedermaier will also be responsible for Investor Relations and Communications. Dr. Georg Weichselbaumer was newly appointed to the Management Board effective July 1, 2019. Dr. Weichselbaumer has been with the company since 2012 as Head of the Basic Chemicals & Synthesis Components Division and will in future head the Sales & Marketing and Research & Development Divisions as Chief Sales Officer (CSO). Mr. Englmaier will continue to serve as Chief Operating Officer (COO). Until the end of the year, Mr. Seibel will continue to be available within the Management Board in an advisory capacity for all areas and will in particular be in charge of the ongoing investment projects.

Markus Zöllner, Chairman of the Supervisory Board of AlzChem Group AG: "With Mr. Niedermaier and Dr. Weichselbaumer, we have appointed proven experts to the new functions. We deliberately opted for an internal solution, as continuity, distinctive company know-how and industry expertise were the most important criteria for the new appointments. We are convinced that AlzChem Group AG will continue its successful development seamlessly in the new Management Board constellation."

About AlzChem
The AlzChem Group is a vertically integrated manufacturer of various chemical products based on the NCN chain. These are products with typical nitrogen-carbon-nitrogen bonding that are used in a wide variety of different industries. The company has a leading position in select niche markets. The strategic focus of growth and the main focus of its extensive research and development are on the business segment Specialty Chemicals. The company has around 1,560 employees at four sites in Germany and three other sites abroad.



03.06.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Solutiance: Hohe Wachstumsdynamik durch den Ausbau des Plattformgeschäfts erwartet

Im ersten Halbjahr 2020 konnte Solutiance den eingeschlagenen Wachstumskurs fortsetzen und im Rahmen dessen die Gesamtleistung (Umsatz zzgl. Bestandsveränderungen) um rund 75 % auf 0,66 Mio. € (1. HJ 2019: 0,38 Mio. €) erhöhen. Das Unternehmen erwartet für das Gesamtjahr durch den weiteren Ausbau der softwarebasierten Dienstleistungen einen Umsatzsprung im Vergleich zum Vorjahr auf rund 3 Mio. €. Bei einem von uns ermittelten Kursziel von 4,85 € vergeben wir das Rating KAUFEN.

Aktuelle Research-Studie

Formycon AG

Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Kaufen

24. September 2020